Revenue segments as reported by the company.

Dialysis patient service revenues

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

General and administrative

Depreciation and amortization

Equity investment income (loss), net

Loss (gain) on changes in ownership interest, net

Goodwill impairment charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

DaVita

DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DaVita reports robust Q4 earnings, navigates challenges with strategic focus

DaVita's Q4 2022 performance reflects financial strength and operational improvements, supported by strategic initiatives and cost discipline.
While facing challenges in operational dynamics and market uncertainties, DaVita remains focused on growth opportunities and patient-centric care.
The company's outlook for 2023 shows a commitment to long-term success through innovation, efficiency, and resilience in a changing healthcare landscape.

DaVita reports strong Q1 earnings and innovation in kidney health

DaVita's Q1 2023 earnings call highlighted strong financial performance, operational efficiency, and a focus on patient care, positioning the company well for future growth and success.
While challenges such as limited operational details and potential labor management issues exist, DaVita's strengths in cost management, innovation, and patient-centric care present opportunities for sustained performance.
Overall, DaVita's positive momentum, revised financial outlook, and commitment to enhancing healthcare services indicate a promising trajectory for the company in the competitive healthcare landscape.

DaVita reports strong Q2 earnings, navigates CMS challenges effectively

DaVita's Q2 2023 performance reflects resilience amidst challenges, with a focus on innovation and operational efficiencies.
The company faces industry headwinds but remains committed to driving growth and enhancing patient care.
Analysts' questions highlighted key concerns and opportunities, showcasing DaVita's proactive approach to addressing industry dynamics.
Overall, DaVita's strategic focus on performance and stakeholder communication positions the company for continued success.

DaVita reports robust Q3 performance and eyes growth opportunities

DaVita's Q3 2023 Earnings Call highlighted strong financial results, operational priorities, and growth prospects. Despite challenges in managing drug impacts and market perception, the company remains focused on delivering quality care and driving shareholder value. Opportunities in CKD progression, shareholder returns, and IKC business improvement position DaVita for future success.

DaVita surpasses 2023 guidance, eyes growth and efficiency in 2024

DaVita's Q4 2023 Earnings Call showcased strong financial performance, exceeding guidance and highlighting a focus on efficiency and cost savings.
While facing challenges like legal proceedings and capacity utilization, DaVita remains optimistic about financial recovery and growth opportunities in 2024.
The company's successful Integrated Kidney Care program and commitment to driving operating performance position it well for continued success in the healthcare market.

DaVita reports robust Q1 earnings, eyes international expansion opportunities

DaVita's Q1 2024 performance reflects strong financial results and a strategic focus on kidney care solutions and international growth.
While challenges like the Change Healthcare outage were addressed, opportunities in expanding markets and enhancing patient care services are evident.
Management's commitment to quality care and sustainable growth positions DaVita well for continued success in the healthcare sector.

DaVita reports robust Q2 earnings, supports CMS proposal for growth

DaVita's Q2 2024 earnings call highlighted strong financial performance and strategic initiatives to drive growth.
While facing challenges in certain operational areas, the company's proactive stance on policy advocacy and financial guidance raise optimism.
Opportunities lie in optimizing operational metrics, managing costs effectively, and engaging stakeholders for sustained growth.

DaVita maintains financial course amidst challenges, eyes growth opportunities

DaVita's Q3 performance met expectations despite supply chain disruptions, with full-year guidance reaffirmed.
The company faces short-term challenges from hurricane impacts and regulatory uncertainties.
Opportunities lie in market changes and growth initiatives, though long-term guidance remains pending.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Duke Energy

Johnson & Johnson

If you are a Johnson & Johnson investor and have been enjoying the stock's steady dividends, it may be time to look elsewhere. As of this moment, we find DaVita - a healthcare company focused on kidney dialysis services - and Duke Energy - an electric and natural gas utility company based in North Carolina - as more attractive buys than Johnson & Johnson.

Drop Johnson & Johnson, Pick These Steady Eddie Stocks?

Philip Morris

Starwood Property

Broad markets, although continuing to trend higher, are showing signs of increasing volatility and uncertainty. While there has been a strong rally in stocks since the sharp correction earlier in the month, there is something peculiar happening under the surface.

3 Defensive Stocks Outperforming in a Choppy Market (PM, DVA, STWD)

Illumina

Two medical stocks with strong momentum and a favorable Zacks Rank are: DVA, ILMN.

2 Must-Buy Medical Stocks With Strong Momentum

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why DaVita HealthCare (DVA) is a Top Value Stock for the Long-Term

Assurant

Marex Group PLC

DVA, MRX and AIZ made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 27, 2024.

Best Momentum Stock to Buy for August 27th

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is DaVita (DVA) Stock Undervalued Right Now?

Apple

American Express

Bank of America

Chubb

Chevron

Kraft Heinz

Coca-Cola

Moody's

Occidental Petroleum

Warren Buffett, the famed ‘ Oracle of Omaha ,' allegedly made his first stock pick at age 11, all the way back in the early 1940s. In the following 80-odd years, he first became a millionaire, then a billionaire, and has perfected the art of getting rich slowly.

Warren Buffett portfolio: Billionaire's top 10 stock picks

DVA stock is up 65% since my last publication, and recent updates show a positive fundamental economics and growth outlook. Q2 earnings exceeded expectations, management forecasts strong growth in operating income and earnings. Embedded expectations are low to see the business trade at $200/share at a 1.9x EV/IC multiple, underlined by cash earnings.

DaVita: Scope For Valuation Upsides With Strengthening Economics (Rating Upgrade)

Pilgrim's Pride

Tenet Healthcare

Universal Health Services

Investors target stocks that have lately been on a bull run. Stocks like PPC, THC, DVA and UHS are seeing price strength and have a high chance of carrying the momentum forward.

4 Stocks Trading Near 52-Week High With More Upside Potential

DaVita HealthCare (DVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

DaVita Inc. (DVA) Hits Fresh High: Is There Still Room to Run?

Does DaVita HealthCare (DVA) have what it takes to be a top stock pick for momentum investors? Let's find out.

DaVita HealthCare (DVA) Is Up 0.56% in One Week: What You Should Know

DaVita stock looks to launch a breakout to an all-time high as 44 A+ funds report a position in the kidney care leader.

Kidney Care Leader Marches Toward Buy Point With 2 Sector Peers In Tow

Brinker International

Cactus

There are better stocks to buy instead of Nvidia (NASDAQ: NVDA ). Although the chipmaker has been an absolute workhorse and promises to radically alter the artificial intelligence landscape, let's be real and admit NVDA stock is not cheap.

Nvidia is Down 21%. Here Are 3 Better Stocks to Buy for the Rest of 2024

DENVER , Aug. 8, 2024 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) ("DaVita") announced today the pricing of its previously announced private offering (the "offering") of $1.0 billion aggregate principal amount of its 6.875% senior notes due 2032 (the "2032 notes"). The 2032 notes were priced at 100.000% of their face amount to yield a 6.875% coupon.

DaVita Inc. Announces Pricing of $1.0 Billion Senior Notes Offering

Is DaVita (DVA) a Great Value Stock Right Now?

Here is how DaVita HealthCare (DVA) and Avadel (AVDL) have performed compared to their sector so far this year.

Are Medical Stocks Lagging DaVita (DVA) This Year?

DENVER , Aug. 8, 2024 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) ("DaVita") announced today that it has commenced a private offering (the "offering") of $1.0 billion aggregate principal amount of its senior notes due 2032 (the "2032 notes"), subject to market and other conditions. DaVita intends to use the net proceeds from the offering to (i) repay a portion of its outstanding Term Loan B-1 facility borrowings maturing in 2026 and a portion of its outstanding revolving credit facility borrowings, in each case, together with related accrued and unpaid interest thereon, (ii) pay any costs, fees and expenses in connection with the foregoing, and (iii) if any proceeds remain, for general corporate purposes, including, without limitation, for repurchases of its capital stock, working capital and capital expenditures.

DaVita Inc. Announces Offering of $1.0 Billion Senior Notes

DaVita's (DVA) robust segmental revenues drive its second-quarter performance.

DaVita (DVA) Q2 Earnings & Revenues Top Estimates, Margins Up

DaVita HealthCare (DVA) came out with quarterly earnings of $2.59 per share, beating the Zacks Consensus Estimate of $2.47 per share. This compares to earnings of $2.08 per share a year ago.

DaVita HealthCare (DVA) Q2 Earnings and Revenues Surpass Estimates

DENVER , Aug. 6, 2024 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended June 30, 2024. "On behalf of all the teammates who provide life-saving care to our patients, I am grateful for the opportunity to report another positive quarter for DaVita," said Javier Rodriguez, CEO of DaVita Inc. "We continue to enhance our clinical capabilities while optimizing our revenue operations and cost structure.

DaVita Inc. 2nd Quarter 2024 Results

Airbnb

Amazon

Baxter

Caterpillar

Disney

Gilead Sciences

Global Payments

Hilton Worldwide Holdings

IDEXX Laboratories

Eli Lilly

Lyft

McDonald's

Martin Marietta Materials

Microsoft

NiSource

Parker-Hannifin

Reddit Inc

Rockwell Automation

Molson Coors Brewing

V.F.

Williams

This marks the last peak week of the Q2 earnings season with 3,908 companies expected to report. Earnings have come in better-than-expected, but tend to be overshadowed by economic data. Outlier earnings this week include: CSX, CAT, and VFC.

The Final Peak Week Of The Q2 Season Begins Amid Souring Economic Data

Improvement in RPT and cost-saving initiatives are likely to have boosted DaVita's (DVA) top line in the second quarter.

Strength in Kidney Care Likely to Aid DaVita's (DVA) Q2 Earnings

Addus HomeCare

Quest Diagnostics

Encompass Health

Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DGX, DVA, EHC and ADUS are well-poised to gain.

4 Stocks to Watch From a Challenging Outpatient Home Health Industry

In the latest trading session, DaVita HealthCare (DVA) closed at $136.47, marking a -1.93% move from the previous day.

DaVita HealthCare (DVA) Suffers a Larger Drop Than the General Market: Key Insights

Floor & Decor Holdings

As the second half of 2024 unfolds, the stock market continues to offer various investment opportunities ranging from large to small-cap equities.

2 Warren Buffett small-cap stocks to turn $100 into $1000 by 2025

News for DaVita Stock (DVA)